Prognostic value of serum P-cadherin level in patients with non-small cell lung cancer / 国际肿瘤学杂志

ABSTRACT

Objective To investigate the prognostic value of serum P-cadherin( P-cad)level in patients with non-small cell lung cancer(NSCLC). Methods A total of 80 patients with NSCLC in Hanzhong 3201 Hospital of Shaanxi Province from January 2012 to December 2013 were selected as study subjects. The relationships between serum P-cad level and clinicopathological characteristics were analyzed. The Cox regres-sion analysis was used to analyze the risk factors affecting prognosis of NSCLC patients. The survival curve was drawn by Kaplan-Meier method and the difference test was carried out by log-rank method. Results There were significant differences in lymph node metastasis(χ2 = 14. 31,P < 0. 001),vascular invasion(χ2 = 5. 56, P = 0. 018)among NSCLC patients with different levels of serum P-cad. Multivariate Cox regression analysis showed that lymph node metastasis(HR = 0. 856,95％ CI0. 702-0. 955,P = 0. 012),TNM stage(ⅢA HR =1. 315,95％ CI1. 058-1. 991,P = 0. 024;ⅢB HR = 1. 448,95％ CI1. 124-2. 215,P = 0. 011;Ⅳ HR =1. 569,95％ CI1. 182-2. 441,P < 0. 001)and high level of serum P-cad(HR = 1. 815,95％ CI1. 224-3. 562,P < 0. 001)were risk factors for progression-free survival in NSCLC patients,and lymph node metasta-sis(HR = 0. 755,95％ CI0. 652-0. 915,P = 0. 022),poor differentiation(HR = 1. 622,95％ CI1. 112-2. 015,P < 0. 001),TNM stage(ⅢA HR = 1. 335,95％ CI1. 064-2. 014,P = 0. 011;ⅢB HR = 1. 489, 95％ CI1. 129-2. 297,P < 0. 001;Ⅳ HR = 1. 622,95％ CI1. 192-2. 501,P < 0. 001)and high level of serum P-cad(HR = 1. 677,95％ CI1. 193-2. 668,P < 0. 001)were risk factors for overall survival of NSCLC patients. The results of Kaplan-Meier survival curve showed that the overall survival and progression-free survival of patients with high level of serum P-cad were shorter than those of patients with low level of serum P-cad(χ2 = 5. 18,P = 0. 015;χ2 = 5. 48,P = 0. 011). Conclusion High level of serum P-cad is closely related to poor prognosis in NSCLC patients.